» Articles » PMID: 34573312

Four New Cases of Hypomyelinating Leukodystrophy Associated with the C.-155_-153delTCA Founder Mutation in Pediatric Patients of Roma Descent in Hungary

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2021 Sep 28
PMID 34573312
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Ufmylation is a relatively newly discovered type of post-translational modification when the ubiquitin-fold modifier 1 (UFM1) protein is covalently attached to its target proteins in a three-step enzymatic reaction involving an E1 activating enzyme (UBA5), E2 conjugating enzyme (UFC1), and E3 ligase enzyme (UFL1). The process of ufmylation is essential for normal brain development and function in humans. Mutations in the gene are associated with Hypomyelinating leukodystrophy type 14, presenting with global developmental delay, failure to thrive, progressive microcephaly, refractive epilepsy, and hypomyelination, with atrophy of the basal ganglia and cerebellum phenotypes. The c.-155_-153delTCA deletion in the promoter region of is considered to be a founding mutation in the Roma population. Here we present four index patients with homozygous :c.-155_-153delTCA mutation detected by next-generation sequencing (whole genome/exome sequencing) or Sanger sequencing. This mutation may be more common in the Roma population than previously estimated, and the targeted testing of the :c.-155_-153delTCA mutation may have an indication in cases of hypomyelination and neurodegenerative clinical course in pediatric patients of Roma descent.

Citing Articles

Hypomyelinating Leukodystrophy 14 (HLD14)-Related UFC1 p.Arg23Gln Decreases Cell Morphogenesis: A Phenotype Reversable with Hesperetin.

Ichihara Y, Okawa M, Minegishi M, Oizumi H, Yamamoto M, Ohbuchi K Medicines (Basel). 2025; 12(1.

PMID: 39846712 PMC: 11755592. DOI: 10.3390/medicines12010002.


Multifaceted roles of UFMylation in health and disease.

Wang R, Li L, Zhou J, Ran J Acta Pharmacol Sin. 2025; .

PMID: 39775503 DOI: 10.1038/s41401-024-01456-9.


A guide to UFMylation, an emerging posttranslational modification.

Millrine D, Peter J, Kulathu Y FEBS J. 2023; 290(21):5040-5056.

PMID: 36680403 PMC: 10952357. DOI: 10.1111/febs.16730.


Severe Epilepsy and Movement Disorder May Be Early Symptoms of -Related Hypomyelinating Leukodystrophy.

Solazzi R, Moscatelli M, Rossi Sebastiano D, Canafoglia L, Pezzoli L, Iascone M Neurol Genet. 2022; 8(5):e200022.

PMID: 36046422 PMC: 9425219. DOI: 10.1212/NXG.0000000000200022.

References
1.
Kugel H, Heindel W, Roth B, Ernst S, Lackner K . Proton MR spectroscopy in infants with cerebral energy deficiency due to hypoxia and metabolic disorders. Acta Radiol. 1998; 39(6):701-10. DOI: 10.3109/02841859809175502. View

2.
Bertoli-Avella A, Beetz C, Ameziane N, Rocha M, Guatibonza P, Pereira C . Successful application of genome sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort. Eur J Hum Genet. 2020; 29(1):141-153. PMC: 7852664. DOI: 10.1038/s41431-020-00713-9. View

3.
Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N . A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 2004; 23(9):1977-86. PMC: 404325. DOI: 10.1038/sj.emboj.7600205. View

4.
Inoue K . PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics. 2005; 6(1):1-16. DOI: 10.1007/s10048-004-0207-y. View

5.
Cheema H, Bertoli-Avella A, Skrahina V, Anjum M, Waheed N, Saeed A . Genomic testing in 1019 individuals from 349 Pakistani families results in high diagnostic yield and clinical utility. NPJ Genom Med. 2020; 5:44. PMC: 7536406. DOI: 10.1038/s41525-020-00150-z. View